Merck KGaA

News

Germany's Merck KGaA is looking at making further acquisitions to boost its business, with a focus on life sciences and rare diseases.

News

Merck KGaA's CEO Belén Garijo will step down next year and will be replaced by the group's electronics boss Kai Beckmann.

News

Industry veteran David Weinreich will step into the top healthcare R&D role at Merck KGaA, following Danny Bar-Zohar's move to lead the division.

News

Merck unit SpringWorks has claimed EU approval for Ogsiveo, becoming the first approved therapy for desmoid tumours in Europe.

News

Merck KGaA has become the latest drugmaker to partner with Skyhawk Therapeutics on its RNA splicing drug discovery engine.

News

Merck gets another quick return on its $3.9bn SpringWorks takeover with EU approval of Ezmekly for tumours caused by neurofibromatosis type 1.